Cystic fibrosis-related diabetes: The unmet need

Pozo, Leonardo; Bello, Fatimah; Mendez, Yamely; Surani, Salim

doi:10.4239/wjd.v11.i6.213

Cited by 4 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CFTR plays a dual role in insulin/glucagon hemostasis. Abnormal intracellular accumulation of chloride in β cells impairs their ability to depolarize in response to glucose, diminishing insulin release [5]. Insulin resistance, malabsorption, liver dysfunction and steroid therapy also may play a role in pathogenesis of CFRD [6].…”

Section: Discussionmentioning

confidence: 99%

Cystic Fibrosis - Related Diabetes

Makuch

2021

J Educ Health Sport

View full text Add to dashboard Cite

Cystic fibrosis (CF) is life-shortening autosomal recessive disease, caused by mutations in the cystic fibrosis transmembrane conductance regulator protein. The most common of CF complications is cystic fibrosis-related diabetes (CFRD). The pathophysiology of CFRD is complex. The best test for screening and diagnosis of CFRD is the oral glucose tolerance test (OGTT). Insulin therapy is a treatment of choice in CFDR pharmacotherapy. An inseparable element of CFRD therapy is also physical activity and diet.

show abstract

Section: Discussionmentioning

confidence: 99%

Cystic Fibrosis - Related Diabetes

Makuch

2021

J Educ Health Sport

View full text Add to dashboard Cite

show abstract

“…However, CFRD constitutes a distinct clinical entity [1]. This differentiation is grounded in its unique physiopathology, which must be understood in clinical attributes, thereby necessitating a specialized approach in terms of its systematic screening, diagnosis, and management, as exemplified in Table 1 [2][3][4].…”

Section: Definitionmentioning

confidence: 99%

An Update in Cystic Fibrosis-Related Diabetes in Children and Adolescents

Anton-Păduraru,

Murgu,

Donos

et al. 2023

Children

View full text Add to dashboard Cite

This paper delineates several aspects of cystic fibrosis-related diabetes (CFRD)—a common complication of cystic fibrosis (CF). CFRD exhibits a predilection for older individuals with CF, yet it also extends its influence on children and adolescents. Scientific insights postulate a potential link between CFRD and the aberrant mucus production within the pancreas, thereby culminating in pancreatic insufficiency. This, in turn, perturbs the synthesis of insulin, a pivotal endocrine hormone responsible for the regulation of glycemic levels. Standardized protocols advocate for the systematic screening of CFRD among all individuals with CF, commencing at the age of 10 years using the oral glucose tolerance test (OGTT). Therapeutic modalities encompass insulin therapy, dietary adjustments, and the vigilant monitoring of glycemic parameters. The overarching objective is to maintain blood glucose levels within a targeted range to mitigate the advent of diabetic complications. Untreated or sub-optimally managed CFRD can precipitate a spectrum of deleterious health ramifications, encompassing cardiovascular afflictions, neuropathy, renal dysfunction, and ocular complications.

show abstract

“…Cystic fibrosis-related diabetes (CFRD) is one of the most common extrapulmonary comorbidities among people with CF, occurring in up to 50% of adults [ 111 ]. CFRD is a form of diabetes caused by relative insulin insufficiency secondary to destruction of pancreatic islets [ 112 , 113 ]. CFRD is associated with worse clinical outcomes, decreased pulmonary function, and higher mortality rates [ 114 ].…”

Section: Using Cgm In Cystic Fibrosis-related Diabetesmentioning

confidence: 99%

Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease

et al. 2023

View full text Add to dashboard Cite

Application of continuous glucose monitoring (CGM) has moved diabetes care from a reactive to a proactive process, in which a person with diabetes can prevent episodes of hypoglycemia or hyperglycemia, rather than taking action only once low and high glucose are detected. Consequently, CGM devices are now seen as the standard of care for people with type 1 diabetes mellitus (T1DM). Evidence now supports the use of CGM in people with type 2 diabetes mellitus (T2DM) on any treatment regimen, not just for those on insulin therapy. Expanding the application of CGM to include all people with T1DM or T2DM can support effective intensification of therapies to reduce glucose exposure and lower the risk of complications and hospital admissions, which are associated with high healthcare costs. All of this can be achieved while minimizing the risk of hypoglycemia and improving quality of life for people with diabetes. Wider application of CGM can also bring considerable benefits for women with diabetes during pregnancy and their children, as well as providing support for acute care of hospital inpatients who experience the adverse effects of hyperglycemia following admission and surgical procedures, as a consequence of treatment-related insulin resistance or reduced insulin secretion. By tailoring the application of CGM for daily or intermittent use, depending on the patient profile and their needs, one can ensure the cost-effectiveness of CGM in each setting. In this article we discuss the evidence-based benefits of expanding the use of CGM technology to include all people with diabetes, along with a diverse population of people with non-diabetic glycemic dysregulation. Supplementary Information The online version contains supplementary material available at 10.1007/s13300-023-01431-3.

show abstract

Cystic fibrosis-related diabetes: The unmet need

Cited by 4 publications

References 24 publications

Cystic Fibrosis - Related Diabetes

Cystic Fibrosis - Related Diabetes

An Update in Cystic Fibrosis-Related Diabetes in Children and Adolescents

Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease

Contact Info

Product

Resources

About